A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of TAK-385 10, 20, and 40 mg (p.o.) in the Treatment of Endometriosis

Trial Profile

A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of TAK-385 10, 20, and 40 mg (p.o.) in the Treatment of Endometriosis

Completed
Phase of Trial: Phase II

Latest Information Update: 19 May 2017

At a glance

  • Drugs Relugolix (Primary) ; Leuprorelin
  • Indications Endometriosis
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 19 May 2017 Primary endpoint (Pain intensity (Score for pelvic pain as measured by the Visual Analogue Scale (VAS), assessed at week 12 (one menstrual cycle), also assessed as a secondary endpoint.)) has been met, according to a Myovant Sciences media release.
    • 19 May 2017 According to a Myovant Sciences media release, results from this trial were presented at the at the 2017 World Congress on Endometriosis.
    • 19 May 2017 Results published in a Myovant Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top